Coherus BioSciences Company Profile (NASDAQ:CHRS)

About Coherus BioSciences

Coherus BioSciences logoCoherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CHRS
  • CUSIP:
Key Metrics:
  • Previous Close: $28.87
  • 50 Day Moving Average: $25.62
  • 200 Day Moving Average: $20.06
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.03
  • P/E Growth: 0.00
  • Market Cap: $1.25B
  • Outstanding Shares: 43,380,000
  • Beta: 5.29
Additional Links:
Companies Related to Coherus BioSciences:

Analyst Ratings

Consensus Ratings for Coherus BioSciences (NASDAQ:CHRS) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $35.50 (22.63% upside)

Analysts' Ratings History for Coherus BioSciences (NASDAQ:CHRS)
Show:
DateFirmActionRatingPrice TargetDetails
8/11/2016Barclays PLCReiterated RatingBuy$46.00View Rating Details
7/27/2016Citigroup Inc.Initiated CoverageBuy$36.00View Rating Details
3/1/2016JPMorgan Chase & Co.Lower Price TargetOverweight$37.00 -> $35.00View Rating Details
1/19/2016Credit Suisse Group AGInitiated CoverageOutperform$25.00View Rating Details
12/1/2014Cowen and CompanyInitiated CoverageOutperform$45.00View Rating Details
(Data available from 8/24/2014 forward)

Earnings

Earnings History for Coherus BioSciences (NASDAQ:CHRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/9/2016Q2($1.32)($1.72)$6.87 million$14.07 millionViewListenView Earnings Details
5/9/2016Q1($1.42)($1.67)ViewListenView Earnings Details
2/29/2016Q4($1.74)($1.35)ViewListenView Earnings Details
11/9/2015Q3($1.86)$16.10 million$7.20 millionViewListenView Earnings Details
8/10/2015Q215($1.56)$488.15 millionViewListenView Earnings Details
5/11/2015Q115($1.22)$488.15 millionViewListenView Earnings Details
3/23/2015Q414($0.46)($1.47)$6.50 millionViewListenView Earnings Details
12/15/2014Q212($1.79)$16.10 millionViewN/AView Earnings Details
3/27/2012($0.02)($0.06)ViewN/AView Earnings Details
12/1/2011($0.09)($0.08)ViewN/AView Earnings Details
9/1/2011$0.01($0.01)ViewN/AView Earnings Details
6/2/2011$0.12$0.17ViewN/AView Earnings Details
3/24/2011($0.19)($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Coherus BioSciences (NASDAQ:CHRS)
Current Year EPS Consensus Estimate: $-6.19 EPS
Next Year EPS Consensus Estimate: $-4.80 EPS

Dividends

Dividend History for Coherus BioSciences (NASDAQ:CHRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Coherus BioSciences (NASDAQ:CHRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/8/2016Fmr LlcInsiderSell100,000$29.86$2,986,000.00View SEC Filing  
8/5/2016Fmr LlcInsiderSell48,600$28.48$1,384,128.00View SEC Filing  
8/1/2016Alan C HermanInsiderSell11,333$25.54$289,444.82View SEC Filing  
7/21/2016Peter K WatlerInsiderSell3,991$26.13$104,284.83View SEC Filing  
7/20/2016Peter K WatlerInsiderSell73,741$25.02$1,844,999.82View SEC Filing  
7/11/2016Peter K WatlerInsiderSell43,495$20.02$870,769.90View SEC Filing  
7/1/2016Alan C HermanInsiderSell4,250$16.89$71,782.50View SEC Filing  
6/1/2016Alan C HermanInsiderSell4,250$18.67$79,347.50View SEC Filing  
5/17/2016Peter K WatlerInsiderSell12,000$20.00$240,000.00View SEC Filing  
5/2/2016Alan C HermanInsiderSell4,250$19.20$81,600.00View SEC Filing  
2/5/2016Alan C HermanInsiderSell2,000$15.02$30,040.00View SEC Filing  
12/1/2015Alan C. HermaninsiderSell11,333$29.49$334,210.17View SEC Filing  
11/13/2015Christos RichardsDirectorSell15,000$27.49$412,350.00View SEC Filing  
11/2/2015Alan C. HermaninsiderSell18,416$28.71$528,723.36View SEC Filing  
10/1/2015Alan C. HermaninsiderSell4,250$18.98$80,665.00View SEC Filing  
9/1/2015Alan C. HermaninsiderSell11,333$27.39$310,410.87View SEC Filing  
8/18/2015Mats WahlstromDirectorSell6,373$33.50$213,495.50View SEC Filing  
8/17/2015Mats WahlstromDirectorSell8,028$33.91$272,229.48View SEC Filing  
8/14/2015Mats WahlstromDirectorSell116,554$34.24$3,990,808.96View SEC Filing  
6/15/2015August J TroendleDirectorSell250,000$26.68$6,670,000.00View SEC Filing  
11/12/2014Eli & Co LillyInsiderBuy164,963$13.50$2,227,000.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Coherus BioSciences (NASDAQ:CHRS)
DateHeadline
News IconIs it Time to Buy Coherus BioSciences, Inc. (NASDAQ:CHRS)? Crowd & Analysts Weigh in - Post News (NASDAQ:CHRS)
www.kentuckypostnews.com - August 24 at 11:00 AM
finance.yahoo.com logoCOHERUS BIOSCIENCES, INC. Financials (NASDAQ:CHRS)
finance.yahoo.com - August 18 at 4:14 PM
capitalcube.com logoETF’s with exposure to Coherus BioSciences, Inc. : August 15, 2016 (NASDAQ:CHRS)
www.capitalcube.com - August 15 at 11:27 AM
capitalcube.com logoCoherus BioSciences, Inc. :CHRS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:CHRS)
www.capitalcube.com - August 12 at 11:49 AM
nasdaq.com logoCoherus BioSciences Submits 351(k) Biologics License Application to U.S. Food ... (NASDAQ:CHRS)
www.nasdaq.com - August 10 at 10:25 PM
fortune.com logoAnalyst Ratings Worth Watching: Coherus Biosciences Inc ... - Review Fortune (NASDAQ:CHRS)
reviewfortune.com - August 10 at 10:46 AM
rttnews.com logoEARNINGS SUMMARY: Details of Coherus Biosciences, Inc. Q2 Earnings Report (NASDAQ:CHRS)
www.rttnews.com - August 9 at 10:00 PM
streetinsider.com logoCoherus BioSciences (CHRS) Announces CHS-1420 Phase 3 Met Primary Endpoint (NASDAQ:CHRS)
www.streetinsider.com - August 9 at 10:00 PM
sg.finance.yahoo.com logoCoherus BioSciences reports 2Q loss (NASDAQ:CHRS)
sg.finance.yahoo.com - August 9 at 10:00 PM
nasdaq.com logoCommit To Purchase Coherus BioSciences At $20, Earn 9% Annualized Using Options (NASDAQ:CHRS)
www.nasdaq.com - August 9 at 4:30 PM
News IconCoherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar… (NASDAQ:CHRS)
forextv.com - August 9 at 4:30 PM
finance.yahoo.com logoCoherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug Administration … (NASDAQ:CHRS)
finance.yahoo.com - August 9 at 4:30 PM
streetinsider.com logoCoherus BioSciences (CHRS) Announces Submission of CHS-1701 BLA to U.S. FDA Under 351(k) Pathway (NASDAQ:CHRS)
www.streetinsider.com - August 9 at 4:30 PM
twst.com logoCoherus BioSciences Inc.: Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results (NASDAQ:CHRS)
www.twst.com - August 9 at 4:30 PM
publicnow.com logoCoherus BioSciences Reports Second Quarter 2016 Financial and Operating Results (NASDAQ:CHRS)
www.publicnow.com - August 9 at 4:30 PM
biz.yahoo.com logoCoherus BioSciences Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:CHRS)
biz.yahoo.com - August 9 at 4:30 PM
News IconCoherus Biosciences Inc (NASDAQ:CHRS): Check on Earnings - Post Registrar (NASDAQ:CHRS)
postregistrar.com - August 9 at 12:01 PM
streetinsider.com logoCoherus BioSciences (CHRS) Announces CHS-1420 Phase 3 Met Primary Endpoint - StreetInsider.com (NASDAQ:CHRS)
www.streetinsider.com - August 9 at 12:01 PM
biz.yahoo.com logoQ2 2016 Coherus BioSciences Inc Earnings Release - After Market Close (NASDAQ:CHRS)
biz.yahoo.com - August 9 at 12:01 PM
nasdaq.com logoCoherus Announces Positive Results For CHS-1420 In Patients With Psoriasis (NASDAQ:CHRS)
www.nasdaq.com - August 8 at 8:59 AM
publicnow.com logoCoherus BioSciences Announces Positive Topline Phase Three Results for CHS-1420 (Humira® Biosimilar Candidate) in Patients with Psoriasis (NASDAQ:CHRS)
www.publicnow.com - August 8 at 8:59 AM
ftsenews.co.uk logoCoherus BioSciences, Inc. (CHRS) Updated Price Targets - FTSE News (NASDAQ:CHRS)
www.ftsenews.co.uk - August 5 at 4:14 PM
tradecalls.org logoCitigroup Initiates Coverage on Coherus Biosciences Inc to Buy ... - Trade Calls (NASDAQ:CHRS)
www.tradecalls.org - August 3 at 4:17 PM
ftsenews.co.uk logoBrokers Issue Average Price Target Of 37.40 On Coherus BioSciences, Inc. (CHRS) - FTSE News (NASDAQ:CHRS)
www.ftsenews.co.uk - July 29 at 9:40 PM
benzinga.com logoCiti Analyst Sees 45-60% Upside In Coherus Biosciences (NASDAQ:CHRS)
www.benzinga.com - July 27 at 12:49 PM
finance.yahoo.com logoCoverage initiated on Coherus BioSciences by Citigroup (NASDAQ:CHRS)
finance.yahoo.com - July 27 at 6:36 AM
publicnow.com logoCoherus BioSciences to Report Second Quarter 2016 Financial Results on August 9th (NASDAQ:CHRS)
www.publicnow.com - July 25 at 11:18 AM
News IconChecking in on Stock Volatility for: Coherus Biosciences, Inc. (NASDAQ:CHRS) - Engelwood Daily (NASDAQ:CHRS)
www.engelwooddaily.com - July 22 at 4:15 PM
News IconCoherus Biosciences Inc on Focus After Crashing In Today's Session - Consumer Eagle (NASDAQ:CHRS)
www.consumereagle.com - July 22 at 4:15 PM
News IconEquity Roundup: Stock Performance Focus on Coherus BioSciences, Inc. (NASDAQ:CHRS) - Press Telegraph (NASDAQ:CHRS)
presstelegraph.com - July 22 at 4:15 PM
News IconCoherus BioSciences, Inc. (NASDAQ:CHRS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:CHRS)
www.engelwooddaily.com - July 22 at 4:15 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Coherus BioSciences, Inc. (NASDAQ:CHRS) - TGP (NASDAQ:CHRS)
telanaganapress.com - July 21 at 7:01 AM
News IconCoherus Biosciences Inc Just Recorded A Sigfniciant Increase - Press Telegraph (NASDAQ:CHRS)
presstelegraph.com - July 21 at 7:01 AM
News IconShares Jumping Higher in Session: Coherus Biosciences, Inc. (NASDAQ:CHRS) - TGP (NASDAQ:CHRS)
telanaganapress.com - July 20 at 5:21 PM
News IconCoherus Biosciences Incorporated (NASDAQ:CHRS) Sellers Increased By 2.15% Their Shorts - Consumer Eagle (NASDAQ:CHRS)
www.consumereagle.com - July 20 at 12:14 PM
News IconInvestor Watch: Volatility Recap on Shares of: Coherus Biosciences, Inc. (NASDAQ:CHRS) - Engelwood Daily (NASDAQ:CHRS)
www.engelwooddaily.com - July 19 at 10:28 AM
News IconAnalyst Target and Average Rating Watch: Coherus BioSciences, Inc. (NASDAQ:CHRS) - Press Telegraph (NASDAQ:CHRS)
presstelegraph.com - July 16 at 7:28 AM
News IconCoherus BioSciences, Inc. (NASDAQ:CHRS) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:CHRS)
telanaganapress.com - July 13 at 4:17 PM
streetupdates.com logoStocks Movements Activity: Rock Creek Pharmaceuticals, Inc. (PNK:RCPI) , Coherus BioSciences, Inc. (NASDAQ:CHRS) - Street Updates (NASDAQ:CHRS)
www.streetupdates.com - July 13 at 4:17 PM
fiscalstandard.com logoBroker Outlook For Coherus BioSciences, Inc. (CHRS) - Fiscal Standard (NASDAQ:CHRS)
www.fiscalstandard.com - July 13 at 4:17 PM
rttnews.com logoCoherus Biosciences Inc. (CHRS) Is Climbing On Study Results - RTT News (NASDAQ:CHRS)
www.rttnews.com - July 13 at 4:17 PM
rttnews.com logoCoherus Biosciences Inc. (CHRS) Rose To Over A 2-Month High On Study Results (NASDAQ:CHRS)
www.rttnews.com - July 12 at 4:19 PM
rttnews.com logoCoherus Biosciences Inc. (CHRS) Rose To Over A 2-Month High On Study Results - RTT News (NASDAQ:CHRS)
www.rttnews.com - July 12 at 8:28 AM
capitalcube.com logoCoherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : July 12, 2016 (NASDAQ:CHRS)
www.capitalcube.com - July 12 at 8:14 AM
nasdaq.com logoCoherus Biosciences Inc. (CHRS) Is Climbing On Study Results (NASDAQ:CHRS)
www.nasdaq.com - July 11 at 4:12 PM
News IconStock Rating Watch and Earnings Insight for Coherus BioSciences, Inc. (NASDAQ:CHRS) - Press Telegraph (NASDAQ:CHRS)
presstelegraph.com - July 11 at 9:01 AM
streetinsider.com logoCoherus BioSciences (CHRS) CHS-1701 Follow-on Study Met All co-Primary Endpoints - StreetInsider.com (NASDAQ:CHRS)
www.streetinsider.com - July 11 at 9:01 AM
finance.yahoo.com logo8:30 am Coherus BioSciences Announces Positive Topline Results for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic and Pharmacodynamic Biosimilarity Study (NASDAQ:CHRS)
finance.yahoo.com - July 11 at 8:30 AM
finance.yahoo.com logoCoherus Announces Positive Topline Results for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic and Pharmacodynamic Biosimilarity Study (NASDAQ:CHRS)
finance.yahoo.com - July 11 at 8:30 AM
fiscalstandard.com logoNext Weeks Broker Price Targets For Coherus BioSciences, Inc. (CHRS) - Fiscal Standard (NASDAQ:CHRS)
www.fiscalstandard.com - July 10 at 4:05 PM

Social

Coherus BioSciences (NASDAQ:CHRS) Chart for Wednesday, August, 24, 2016


Last Updated on 8/24/2016 by MarketBeat.com Staff